Despite the geopolitical pressure, the Timor approval and WDS merger talk, STO has struggled to fund a bid. Conversely, the recent coal import numbers from China showed a 35% increase in coal imports
CSL continues to rally @ $281. Original position was 8% allocation. Today trim another 2% to take down to 4% allocation.
Add Telix Pharma (TLX) in our balanced portfolio, capitalizing on Telix’s innovative cancer treatment advancements and market potential.
The Nasdaq hedge is unlikely to work over the short-term as the thesis of the rate hiking cycle being finished, combined with the 70% occurrence of a “Christmas Rally”
Investing 1% of our portfolio allocation in PLS presents a compelling opportunity. PLS stands as the most shorted stock on the ASX, with a substantial 20.45% short interest. This indicates potential for a short squeeze, which could lead to a rapid price increase.
URNM provides exposure to leading global companies involved in the mining, exploration, development and production of uranium, modern nuclear energy, or that hold physical uranium or uranium royalties
Sell 2.5% holding in Ventia services for 10% profit
The CSL position that we put on initially is now 10% in the money. We are looking to trim 2% or 1/4 of our position to take a profit.
Macquarie Bank is set to announce earnings, consistently demonstrating a remarkable record of exceeding expectations. MQG is a cornerstone in our portfolios, showcasing reliable performance. We advise purchasing a 2%-4% allocation of MQG shares on Thursday, anticipating a potential gap-up at Friday’s market open, following the release of positive updates.
Shifting from Ventia to IPD, leveraging Ventia’s 9% return for IPD’s undervalued potential, aligns with our strategy for value-driven, defensive investment opportunities.
Switching from Neuren Pharma (NEU) to Telix Pharma (TLX) in our balanced portfolio, capitalizing on Telix’s innovative cancer treatment advancements and market potential.
